Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study questions unnecessary antifungal use in intensive care

NCT ID NCT03774316

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether it's safe to reduce or stop antifungal drugs early in immunocompromised ICU patients suspected of having a fungal infection. Researchers tracked 275 patients across 14 ICUs to see how often doctors de-escalated treatment and what factors influenced that decision. The goal is to learn how to avoid unnecessary side effects and drug resistance without harming patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors safely reduce unnecessary antifungal use in ICU patients, lowering side effects and costs.
What could go wrong
This is an observational study, not a treatment trial. It only looks at patterns and safety, so it won't prove a new therapy works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

275 people

The number who actually took part.

Started

Jan 2019

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults immunocompromised patients hospitalized in intensive care units (Age ≥18 years) Immunosuppression is defined by: * long-term immunosuppressive therapy (\> 3 months) or high-dose corticosteroid therapy (\> 0.5 mg / kg / day for at least 3 days) * Solid organ transplant * Solid cancer (active or in remission since \<5 years) * Malignant haemopathy * HIV infection with CD4 \<200

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults immunocompromised patients hospitalized in intensive care units * Predictable invasive mechanical ventilation duration \> 96h * Signed consent (by patient or its representative) * First antifungal treatment initiation in ICU for proven or suspected candida infection Exclusion Criteria: * Pregnant or breast-feeding women. * Fungal infection other than invasive candida * Prophylactic antifungal treatment. * Lack of informed consent * Predictable mechanical ventilation duration less than 48 hours * Patients discharged from ICU before the 5th day after initiation of TAF

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidiasis, invasive Critical Illness disseminated candidiasis Invasive Fungal Infections systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Invasive fungal disease

Contacts and locations

Locations

  • CHU Lille

    Lille, 59000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.